SCHEMBL846854

SCHEMBL846854

Cc1ccc(N=C=S)c(Cl)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.35
GABRG2 P18507 2/20 0.35
GABRB3 P28472 2/20 0.35
GABRB2 P47870 2/20 0.35
ALDH1A1 P00352 4/20 0.33
CYP1A2 P05177 3/20 0.33
HPGD P15428 3/20 0.33
CYP3A4 P08684 2/20 0.33
ADRA2A P08913 2/20 0.33
LMNA P02545 2/20 0.33
ABCB11 O95342 1/20 0.33
NR3C1 P04150 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ALOX15 P16050 1/20 0.33
ADRA2C P18825 1/20 0.33
MAOA P21397 1/20 0.33
DRD1 P21728 1/20 0.33
SLC6A4 P31645 1/20 0.33
HTR2B P41595 1/20 0.33
CCR2 P41597 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2697378 0.84 ALDH1A1 (0.33) GABRA1GABRG2GABRB3GABRB2ALDH1A1
SCHEMBL1457687 0.80 ALDH1A1 (0.34) ALDH1A1CYP1A2HPGDCYP3A4ADRA2A
SCHEMBL3841180 0.80 CYP3A4 (0.45) GABRA1GABRG2GABRB3GABRB2ALDH1A1
SCHEMBL30673505 0.80 ALDH1A1 (0.34) ALDH1A1CYP1A2HPGDCYP3A4ADRA2A
SCHEMBL30421135 0.79 NPC1 (0.46) ALDH1A1CYP1A2HPGDCYP3A4ADRA2A
SCHEMBL945304 0.79 NPC1 (0.46) ALDH1A1CYP1A2HPGDCYP3A4ADRA2A
SCHEMBL29668125 0.79 ITGB3 (0.43) ALDH1A1CYP1A2HPGDCYP3A4ADRA2A
SCHEMBL1021797 0.79 ITGB3 (0.43) ALDH1A1CYP1A2HPGDCYP3A4ADRA2A
SCHEMBL15581839 0.78 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL17289576 0.78 TDP1 (0.44) GABRA1GABRB2ALDH1A1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed
EP-0876355-A1 2-THIOXO-IMIDAZOLIDIN-4-ONE DERIVATIVES AND THEIR USE FOR INCREASING HDL CHOLESTEROL CONCENTRATION AMERICAN HOME PRODUCTS CORPORATION (US) 1998-11-11 EP disclosed
WO-1997019932-A1 2-THIOXO-IMIDAZOLIDIN-4-ONE DERIVATIVES AND THEIR USE FOR INCREASING HDL CHOLESTEROL CONCENTRATION AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-05 WO disclosed
US-5554607-A INCREASING HDL CHOLESTEROL AMERICAN HOME PRODUCTS CORPORATION (US) 1996-09-10 US disclosed
US-5393883-A Ribonucleotide reductase inhibitors BURROUGHS WELLCOME CO. (US) 1995-02-28 US disclosed
US-5175165-A Acyclovir and a thiocarbonohydrazone ribonucleotide reductase inhibitor for treatment of herpes virus BURROUGHS WELLCOME CO. (US) 1992-12-29 US disclosed
EP-0349243-B1 ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR THE WELLCOME FOUNDATION LIMITED (GB) 1992-04-01 EP disclosed
EP-0349243-A2 Antiviral combinations and compounds therefor THE WELLCOME FOUNDATION LIMITED (GB) 1990-01-03 EP disclosed
US-4039575-A Alkanimidoylthioureas STERLING DRUG INC. (US) 1977-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135929-A1 Methods Of Modulating Uric Acid Levels XDH, PON1, OAT GABRA1 1988/4885GABRG2 2617/4885GABRB3 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.